Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ASTH Stock Forecast 2026-2027
$44.94
Current Price
$2.33B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ASTH Price Targets
+17.9%
To High Target of $53.00
+4.6%
To Median Target of $47.00
-8.8%
To Low Target of $41.00
ASTH Price Momentum
-4.1%
1 Week Change
+14.7%
1 Month Change
+98.4%
1 Year Change
+81.1%
Year-to-Date Change
-12.9%
From 52W High of $51.60
+148.6%
From 52W Low of $18.08
📊 TOP ANALYST CALLS
Did ASTH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Astrana Health is one of their latest high-conviction picks.
Latest ASTH Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ASTH has a bullish consensus with a median price target of $47.00 (ranging from $41.00 to $53.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $44.94, the median forecast implies a 4.6% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ASTH Analyst Ratings
10
Buy
1
Hold
0
Sell
ASTH Price Target Range
Low
$41.00
Average
$47.00
High
$53.00
Current: $44.94
Latest ASTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ASTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 14, 2026 | TD Cowen | Ryan Langston | Buy | Maintains | $50.00 |
| Jul 14, 2026 | BTIG | David Joyce | Buy | Maintains | $65.00 |
| Jun 2, 2026 | BTIG | David Larsen | Buy | Reiterates | $50.00 |
| May 26, 2026 | Barclays | Andrew Mok | Overweight | Upgrade | $50.00 |
| May 14, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 12, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| May 11, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| May 8, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 8, 2026 | Needham | Buy | Maintains | $N/A | |
| Apr 15, 2026 | Baird | Outperform | Maintains | $N/A | |
| Mar 13, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Feb 2, 2026 | BTIG | Buy | Maintains | $N/A | |
| Dec 12, 2025 | Needham | Buy | Initiates | $N/A | |
| Nov 25, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Nov 24, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Nov 10, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Nov 7, 2025 | BTIG | Buy | Maintains | $N/A | |
| Apr 1, 2025 | Barclays | Equal-Weight | Initiates | $N/A | |
| Mar 18, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Mar 4, 2025 | B of A Securities | Buy | Maintains | $N/A |
Astrana Health Inc. (ASTH) Competitors
The following stocks are similar to Astrana Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Astrana Health Inc. (ASTH) Financial Data
Astrana Health Inc. has a market capitalization of $2.33B with a P/E ratio of 77.8x. The company generates $3.53B in trailing twelve-month revenue with a 0.9% profit margin.
Revenue growth is +55.6% quarter-over-quarter, while maintaining an operating margin of +3.0% and return on equity of +5.7%.
Valuation Metrics
Market Cap
$2.33B
Enterprise Value
$2.79B
P/E Ratio
77.8x
PEG Ratio
0.7x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+55.6%
Gross Margin
+11.0%
Operating Margin
+3.0%
Net Margin
+0.9%
EPS Growth
+115.7%
Financial Health
Cash/Price Ratio
+21.5%
Current Ratio
1.3x
Debt/Equity
184.5x
ROE
+5.7%
ROA
+3.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Astrana Health Inc. (ASTH) Business Model
About Astrana Health Inc.
What They Do
Healthcare management company leveraging technology.
Business Model
The company operates through three segments: Care Partners, Care Delivery, and Care Enablement, generating revenue by providing integrated healthcare services and care coordination. It leverages a proprietary platform to empower healthcare providers to deliver value-based, high-quality care, aligning incentives with patient outcomes.
Additional Information
Founded in 1985 and headquartered in Alhambra, California, the company plays a crucial role in the value-based care sector, emphasizing operational efficiency and cost-effective care delivery across a broad network of healthcare professionals and facilities.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
3,000
CEO
Mr. Brandon K. Sim M.S.
Country
United States
IPO Year
2007
Website
www.astranahealth.comAstrana Health Inc. (ASTH) Latest News & Analysis
Latest News
Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call
3 days ago
Quick Summary
Astrana Health, Inc. (NASDAQ: ASTH) will release its Q2 2026 financial results on August 6, 2026, after market close.
Why It Matters
Astrana Health's upcoming financial results release could impact investor sentiment and stock performance, signaling the company's growth and operational health in the healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Astrana Health, Inc. (NASDAQ: ASTH) appointed Daniel Rothman as President of Physician Enterprise and Vishal Gupta as Senior VP of Enterprise Transformation on July 13, 2026.
Why It Matters
Leadership changes at Astrana Health may signal strategic shifts, impacting operational efficiency and growth potential, which could influence stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Astrana Health ACOs Deliver $120.4 Million in Gross Shared Savings in 2024 Performance Year
4 days ago
Quick Summary
Astrana Health's ACOs generated $120.4 million in gross shared savings for the 2024 performance year, indicating successful cost management and efficiency in healthcare delivery.
Why It Matters
The announcement of $120.4 million in gross shared savings by Astrana's ACOs signals strong operational efficiency and potential for increased profitability, likely boosting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Astrana Health, Inc. (ASTH) shares rose significantly with above-average trading volume, although recent earnings estimate revisions may not lead to further price increases soon.
Why It Matters
Astrana Health's share surge and high trading volume indicate heightened investor interest, but revised earnings estimates suggest potential price stabilization ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Astrana Health, Inc. (NASDAQ: ASTH) has been named to the Fortune 1000® for 2026, marking its first appearance on the list of largest U.S. companies by revenue.
Why It Matters
Astrana Health's inclusion in the Fortune 1000 indicates strong revenue growth and market recognition, which could enhance investor confidence and potentially drive stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Astrana Health (NASDAQ: ASTH) reports early benefits from its Prospect acquisition, with stronger-than-expected trends in medical costs, free cash flow, and revenue for Q1.
Why It Matters
Positive early results from the Prospect acquisition and stronger-than-expected financial trends indicate potential growth and profitability for Astrana Health, boosting investor confidence.
Source: MarketBeat
Market Sentiment:
Positive
Frequently Asked Questions About ASTH Stock
What is Astrana Health Inc.'s (ASTH) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Astrana Health Inc. (ASTH) has a median price target of $47.00. The highest price target is $53.00 and the lowest is $41.00.
Is ASTH stock a good investment in 2027?
According to current analyst ratings, ASTH has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $44.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ASTH stock?
Wall Street analysts predict ASTH stock could reach $47.00 in the next 12 months. This represents a 4.6% increase from the current price of $44.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Astrana Health Inc.'s business model?
The company operates through three segments: Care Partners, Care Delivery, and Care Enablement, generating revenue by providing integrated healthcare services and care coordination. It leverages a proprietary platform to empower healthcare providers to deliver value-based, high-quality care, aligning incentives with patient outcomes.
What is the highest forecasted price for ASTH Astrana Health Inc.?
The highest price target for ASTH is $53.00 from at , which represents a 17.9% increase from the current price of $44.94.
What is the lowest forecasted price for ASTH Astrana Health Inc.?
The lowest price target for ASTH is $41.00 from at , which represents a -8.8% decrease from the current price of $44.94.
What is the overall ASTH consensus from analysts for Astrana Health Inc.?
The overall analyst consensus for ASTH is bullish. Out of 5 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $47.00.
How accurate are ASTH stock price projections?
Stock price projections, including those for Astrana Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:07 AM UTC